Menopause: HRT or No HRT?

In a recent study, midlife women with prediabetes before menopause transition were more likely to experience fractures in postmenopause.

In this episode, Michael Krychman, MD, sat down with Alyssa Dweck, MD, gynecologist, and Bonafide medical advisor to catch up at this year's North American Menopause Society (NAMS) Annual Meeting.

Fezolinetant (Veozah; Astellas Pharma) is now the first neurokinin 3 receptor antagonist approved for the treatment of vasomotor symptoms associated with menopause.

Actress Kim Cattrall discusses her menopause journey and partnership with Tune In To Menopause, an awareness campaign designed to empower women.

In a recent study, menopausal vasomotor symptoms were successfully treated using the selective neurokinin-1,3 receptor antagonist elinzanetant (Bayer).

Multiple hormonal and non-hormonal therapies are available for treating genitourinary syndrome of menopause in breast cancer survivors, but combination therapies are the most effective.